Tumor Treating Fields, also known as TTFields, is an innovative treatment option for some cancers. Through the use of alternating electric fields, TTFields aim to disrupt cancer cell division and stop tumor growth. As a focal treatment, it has shown promise for certain advanced cancers. In this article, we explore what TTFields are and how they work, current applications and research, as well as considerations for patients.
What are TTFields?
TTFields are low-intensity electric fields that are administered through transducer arrays placed on the skin. These transducer arrays generate alternating electric fields at an intermediate frequency (100-300 kHz) within the body. The fields disrupt cancer cell division and halt proliferation by interfering with normal mitotic spindle formation and chromosome separation during cytokinesis.
Normal cell division requires precise spatial organization and alignment of charged proteins and other structures. The alternating electric fields generated by TTFields disrupt this organization, causing aberrant mitosis and programmed cell death - specifically affecting faster dividing cancer cells while leaving slower dividing normal cells mostly unharmed. Studies indicate TTFields can induce cancer cell death via mitotic catastrophe.
How TTFields Therapy Works
For Tumor Treating Fields therapy to be effective, the intermediate frequency electric fields must be able to penetrate deep into the body and impact dividing cancer cells. Cancer cells are typically more vulnerable due to their accelerated rate of division compared to normal cells.
Four transducer arrays, consisting of insulated electrode layers and hydrogel for conductivity, are attached to the skin around the tumor site. These generate low-intensity 200 kHz alternating electric fields within the body. Cancer cells attempt to divide but become arrested in mitosis as the polarized structures cannot correctly organize due to field interference. This prevents cellular reproduction and tumor growth.
Current Applications and Research
TTFields therapy has been approved as a treatment for recurrent glioblastoma and malignant pleural mesothelioma based on Phase 3 clinical trial data demonstrating improved progression-free and overall survival compared to chemotherapy. It is administered concurrently with maintenance temozolomide chemotherapy for glioblastoma.
Ongoing research is exploring TTFields' potential for other solid tumor types. Early results have shown promise in pancreatic cancer, non-small cell lung cancer, ovarian cancer and other advanced solid tumors. Combination approaches using TTFields with immunotherapy, targeted therapy or chemotherapy are also under investigation to heighten anti-tumor responses.
Trials are also assessing the viability of TTFields as a primary treatment, maintenance therapy following primary treatment, or as an adjuvant to increase response rates to other modalities like radiation or surgery. Safety and efficacy studies continue to expand approved uses for this non-invasive focal therapy approach.
Benefits and Considerations
TTFields therapy offers several distinct patient benefits as a focal treatment approach. Administration is non-invasive through external transducer arrays, avoiding risks of invasive surgery or interventional procedures. Treatment can be performed in the outpatient setting or at home, preserving quality of life.
Early research demonstrates a convenient side effect profile as the low intensity fields impact rapidly dividing cells selectively without affecting surrounding normal tissues. Toxicity is mild and tolerable compared to chemotherapy. However, device use can cause skin irritation at placement sites requiring proper application and maintenance.
Costs of the delivering device and ongoing maintenance require consideration and insurance approval for coverage. Ongoing trials also aim to define optimal patient selection criteria to maximize benefits for subsets most responsive to TTFields. Overall, it presents a promising new treatment paradigm for improving outcomes in hard-to-treat advanced cancers when used appropriately.
In summary, Tumor Treating Fields present an innovative non-invasive focal therapy approach through application of intermediate frequency alternating electric fields. Research substantiates TTFields' ability to disrupt cancer cell division specifically while sparing surrounding normal cells. Approved uses so far include recurrent glioblastoma and mesothelioma maintenance based on improved clinical outcomes.
Ongoing studies continue expanding its applications to other solid tumors, assessing optimal integration with other modalities, and refining patient selection criteria. Benefits include mild toxicity profile, ambulatory administration preserving quality of life compared to more invasive alternatives. While costs require consideration, TTFields therapy offers promising potential to impact outcomes for certain advanced cancers undergoing active cellular division. Further research will help optimize its clinical application and identify additional eligible patient populations.
Get more insights on- Tumor Treating Fields